Byrjalsen 1992.

Methods	Randomisation: method not stated Single‐blind, parallel‐group, placebo‐controlled, single centre Number of women randomised: 73 Number of women analysed: 66 Number of early withdrawals: 7 (3 because of vaginal bleeding, 1 because of oedema of the legs, 2 because of lack of time, 1 because of illness unrelated to study)
Participants	Country: Denmark Inclusion criteria: healthy postmenopausal women aged 45 to 54 years who had experience natural menopause 9 to 40 months previously Exclusion criteria: diseases or concomitant medications known to influence study measurements
Interventions	Sequential vs sequential vs placebo (A) 2 mg EV days 1 to 21 + 10 mg MPA daily days 12 to 21 (B) 1.5 mg E2 days 1 to 24 + 150 µg DG days 13 to 24 (C) placebo Duration: 2 years
Outcomes	Mean duration of withdrawal bleed, amenorrhoea, endometrial biopsy
Power calculation described	No
Analysis by Intention to Treat	No
Notes	‐
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of sequence generation not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding (performance bias and detection bias) All outcomes	Low risk	Single blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	73 women were randomised to 3 groups. Biopsies at the end of the study on 56 women (77% of those randomised)
Other bias	Low risk	3 groups balanced at baseline